Abstract
Emergence of resistance to antifungal drugs during therapy for invasive aspergillosis has received scant attention. We recovered Aspergillus isolates from six patients with invasive aspergillosis, who were receiving amphotericin B before fungal isolation. Although isolates were susceptible to amphotericin B in vitro, none of the patients survived. The MIC of amphotericin B for isolates was similar to that for isolates from 35 patients with no prior exposure to amphotericin B. Laboratory attempts to produce amphotericin B resistance in Aspergillus were unsuccessful. These data indicate that emergence of resistance to amphotericin B is uncommon during therapy for invasive aspergillosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 209-213 |
| Number of pages | 5 |
| Journal | Journal of Antimicrobial Chemotherapy |
| Volume | 49 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2002 |
ASJC Scopus subject areas
- Pharmacology
- Microbiology (medical)
- Infectious Diseases
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis'. Together they form a unique fingerprint.
Cite this
Moosa, M. Y. S., Alangaden, G. J., Manavathu, E., & Chandrasekar, P. H. (2002). Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis. Journal of Antimicrobial Chemotherapy, 49(1), 209-213. https://doi.org/10.1093/jac/49.1.209